{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T22:08:42Z","timestamp":1770761322871,"version":"3.50.0"},"reference-count":191,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Chronic hepatitis B (CHB), a chronic liver infectious disease, results from persistent hepatitis B virus (HBV) infection lasting over 6\u00a0months. It has become a substantial global public health burden. CHB is often manifested by concomitant hepatic biochemical abnormalities, and\/or notable inflammatory necrosis, and\/or liver histological fibrosis. If left uncontrolled, CHB can progress to severe liver diseases and may even lead to death. Although currently approved therapeutic agents can effectively suppress viral replication and, to a certain extent, reduce related complications, their ineffectiveness in targeting covalently closed circular DNA (cccDNA) fundamentally restricts their potential to achieve a clinical cure. In recent years, research focused on attaining a functional cure for CHB has been on the rise. Drugs with different targeting mechanisms and diverse therapeutic strategies have rendered a clinical cure for CHB a possibility. Among these, emerging small nucleic acid drugs show great promise, exhibiting high potential for achieving a sustained functional cure. In this review, we systematically investigate the unique structure of the HBV genome. Moreover, we delve into the classification, mechanisms of action, and pathways for small nucleic acid drugs used in CHB treatment to achieve a functional cure. Additionally, we analyze some challenges encountered in the development of these drugs and propose corresponding solutions. Furthermore, we discuss current clinical studies and combination therapies involving small nucleic acid drugs for CHB treatment.<\/jats:p>","DOI":"10.3389\/fphar.2025.1633001","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T05:32:05Z","timestamp":1758864725000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Small nucleic acid drugs-the dawn of functional cure of chronic hepatitis B"],"prefix":"10.3389","volume":"16","author":[{"given":"Lu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijing","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shourong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rangxiao","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jhep.2022.08.020","article-title":"Antisense oligonucleotides (ASOs) in chronic hepatitis B infection: opportunities and challenging the orthodoxy","volume":"77","author":"Agarwal","year":"2022","journal-title":"J. Hepatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jhep.2024.03.046","article-title":"JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2","volume":"81","author":"Agarwal","year":"2024","journal-title":"J. Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/mmbr.67.4.657-685.2003","article-title":"RNA interference: biology, mechanism, and applications","volume":"67","author":"Agrawal","year":"2003","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"102237","DOI":"10.1016\/j.omtn.2024.102237","article-title":"Strategies to improve the design of gapmer antisense oligonucleotide on allele-specific silencing","volume":"35","author":"Aguti","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","article-title":"Engineering siRNA therapeutics: challenges and strategies","volume":"21","author":"Ali Zaidi","year":"2023","journal-title":"J. Nanobiotechnology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/jcph.2337","article-title":"Pharmacokinetics and pharmacodynamics of GalNAc\u2010Conjugated siRNAs","volume":"64","author":"An","year":"2023","journal-title":"J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/s2468-1253(19)30190-6","article-title":"Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterology and Hepatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jhep.2014.10.004","article-title":"miR-122 \u2013 a key factor and therapeutic target in liver disease","volume":"62","author":"Bandiera","year":"2015","journal-title":"J. Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"101205","DOI":"10.1016\/j.coviro.2022.101205","article-title":"Advances in human monoclonal antibody therapy for HBV infection","volume":"53","author":"Beretta","year":"2022","journal-title":"Curr. Opin. Virol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jhep.2015.11.032","article-title":"In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides","volume":"64","author":"Billioud","year":"2016","journal-title":"J. Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/nar\/gky1239","article-title":"Diverse lipid conjugates for functional extra-hepatic siRNA deliveryin vivo","volume":"47","author":"Biscans","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jconrel.2022.07.041","article-title":"Engineered ionizable lipid siRNA conjugates enhance endosomal escape but induce toxicity in vivo","volume":"349","author":"Biscans","year":"2022","journal-title":"J. Control. Release"},{"key":"B14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-pharmtox-010715-103633","article-title":"RNA interference (RNAi)-Based therapeutics: delivering on the promise?","volume":"56","author":"Bobbin","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/genes9070365","article-title":"Cellular genomic sites of hepatitis B virus DNA integration","volume":"9","author":"Budzinska","year":"2018","journal-title":"Genes (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1039\/c1cs15048k","article-title":"Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals","volume":"40","author":"Campbell","year":"2011","journal-title":"Chem. Soc. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.2174\/1381612829666230220123150","article-title":"miRNA as drug: antagomir and beyond","volume":"29","author":"Cannataro","year":"2023","journal-title":"Curr. Pharm. Des."},{"key":"B18","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","article-title":"Antisense oligonucleotides: from design to therapeutic application","volume":"33","author":"Chan","year":"2006","journal-title":"Clin. Exp. Pharmacol. Physiology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11095-007-9504-0","article-title":"RNAi for treating hepatitis B viral infection","volume":"25","author":"Chen","year":"2007","journal-title":"Pharm. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e22164","DOI":"10.1002\/ddr.22164","article-title":"The current perspective and opportunities of small nucleic acid-based therapeutics","volume":"85","author":"Chen","year":"2024","journal-title":"Drug Dev. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV treatment endpoints conference\u2021","volume":"72","author":"Cornberg","year":"2020","journal-title":"J. Hepatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B26","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"B27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00281-020-00780-6","article-title":"Epigenetic modulation in chronic hepatitis B virus infection","volume":"42","author":"Dandri","year":"2020","journal-title":"Seminars Immunopathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"eabf4077","DOI":"10.1126\/scitranslmed.abf4077","article-title":"An ASO therapy for angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript","volume":"15","author":"Dindot","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"B30","article-title":"HBsAg loss and seroconversion in HBeAg-negative chronic hepatitis B subjects on NA therapy after AHB-137 treatment: preliminary data from an ongoing multicenter, randomized, open-label phase IIa study","volume-title":"Annual meeting of the American association for the study of liver diseases (AASLD) 2024","author":"Ding","year":"2024"},{"key":"B31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1089\/hum.2013.234","article-title":"Development of therapeutic splice-switching oligonucleotides","volume":"25","author":"Disterer","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/nat.2014.0506","article-title":"Phosphorothioates, essential components of therapeutic oligonucleotides","volume":"24","author":"Eckstein","year":"2014","journal-title":"Nucleic Acid. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2018.01.003","article-title":"Strategies to overcome HBV-Specific T cell exhaustion: checkpoint inhibitors and metabolic re-programming","volume":"30","author":"Fisicaro","year":"2018","journal-title":"Curr. Opin. Virology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: state-of-the-Art and future perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1093\/jac\/dkr388","article-title":"Nucleoside\/nucleotide analogues in the treatment of chronic hepatitis B","volume":"66","author":"Fung","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hep.32314","article-title":"Getting to HBV cure: the promising paths forward","volume":"76","author":"Fung","year":"2022","journal-title":"Hepatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/03036758.2020.1811355","article-title":"The roadmap towards cure of chronic hepatitis B virus infection","volume":"52","author":"Gane","year":"2020","journal-title":"J. R. Soc. N. Z."},{"key":"B38","article-title":"A phase 1, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of AHB-137 in Chinese healthy volunteers and subjects with chronic hepatitis B","volume-title":"Annual meeting of the european association for the study of the liver (EASL) 2024","author":"Gane","year":"2024"},{"key":"B39","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/s0168-8278(20)30597-3","article-title":"Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment","volume":"73","author":"Gane","year":"2020","journal-title":"J. Hepatology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"13596535221093856","DOI":"10.1177\/13596535221093856","article-title":"JNJ-73763989 pharmacokinetics and safety: liver-targeted siRNAs against hepatitis B virus, in Japanese and Non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B","volume":"27","author":"Gane","year":"2022","journal-title":"Antivir. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jhep.2023.05.023","article-title":"Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials","volume":"79","author":"Gane","year":"2023","journal-title":"J. Hepatology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40268-021-00369-w","article-title":"Clinical and preclinical single-dose pharmacokinetics of VIR-2218, an RNAi therapeutic targeting HBV infection","volume":"21","author":"Gupta","year":"2021","journal-title":"Drugs R&D"},{"key":"B43","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/15476286.2022.2027150","article-title":"Innovative developments and emerging technologies in RNA therapeutics","volume":"19","author":"Halloy","year":"2022","journal-title":"RNA Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.cell.2006.03.043","article-title":"Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex","volume":"125","author":"Han","year":"2006","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpdd.1154","article-title":"Preclinical and phase 1 assessment of antisense oligonucleotide bepirovirsen in hepatitis B virus\u2013transgenic mice and healthy human volunteers: support for clinical dose selection and evaluation of safety, tolerability, and pharmacokinetics of single and multiple doses","volume":"11","author":"Han","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1147379","DOI":"10.3389\/fimmu.2023.1147379","article-title":"Inhibition of macrophages inflammasome activation via autophagic degradation of HMGB1 by EGCG ameliorates HBV-induced liver injury and fibrosis","volume":"14","author":"He","year":"2023","journal-title":"Front. Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3390\/pharmaceutics14081708","article-title":"Towards personalized allele-specific antisense oligonucleotide therapies for toxic gain-of-function neurodegenerative diseases","volume":"14","author":"Helm","year":"2022","journal-title":"Pharmaceutics"},{"key":"B48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1275","article-title":"The four Rs of RNA-directed evolution","volume":"36","author":"Herbert","year":"2003","journal-title":"Nat. Genet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e100951","DOI":"10.1371\/journal.pone.0100951","article-title":"Anti-miRs competitively inhibit microRNAs in Argonaute complexes","volume":"9","author":"Hogan","year":"2014","journal-title":"PLoS One"},{"key":"B50","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/15476286.2022.2066334","article-title":"Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases","volume":"19","author":"Holm","year":"2022","journal-title":"RNA Biol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"102351","DOI":"10.1016\/j.omtn.2024.102351","article-title":"Mechanistic insights into ASO-RNA complexation: advancing antisense oligonucleotide design strategies","volume":"35","author":"H\u00f6rberg","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B52","doi-asserted-by":"publisher","first-page":"297","DOI":"10.14218\/jcth.2016.00019","article-title":"Guideline of prevention and treatment for chronic hepatitis B (2015 update)","volume":"5","author":"Hou","year":"2017","journal-title":"J. Clin. Transl. Hepatology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3350\/cmh.2022.0420","article-title":"Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: first, do no harm","volume":"29","author":"Hsu","year":"2023","journal-title":"Clin. Mol. Hepatology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","article-title":"Preclinical and clinical advances of GalNAc-Decorated nucleic acid therapeutics","volume":"6","author":"Huang","year":"2017","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B55","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3350\/cmh.2022.0012","article-title":"RNA interference as a novel treatment strategy for chronic hepatitis B infection","volume":"28","author":"Hui","year":"2022","journal-title":"Clin. Mol. Hepatology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40259-024-00694-x","article-title":"Investigational RNA interference agents for hepatitis B","volume":"39","author":"Hui","year":"2024","journal-title":"BioDrugs"},{"key":"B57","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nbt.3948","article-title":"Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides","volume":"35","author":"Iwamoto","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd3010","article-title":"Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application","volume":"9","author":"Jackson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting MicroRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2161254","DOI":"10.1080\/21645515.2022.2161254","article-title":"The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance","volume":"19","author":"Jiang","year":"2023","journal-title":"Hum. Vaccin Immunother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.tips.2023.08.008","article-title":"ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis","volume":"44","author":"Jin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.7150\/thno.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging","volume":"12","author":"Jung","year":"2022","journal-title":"Theranostics"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2174\/1389201023666220114160216","article-title":"Antisense agents against antibiotic-resistant bacteria","volume":"23","author":"Kafil","year":"2022","journal-title":"Curr. Pharm. Biotechnol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s40265-020-01400-1","article-title":"Bulevirtide: first approval","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"key":"B66","doi-asserted-by":"publisher","first-page":"10462","DOI":"10.3390\/ijms221910462","article-title":"Toll-like receptor response to hepatitis B virus infection and potential of TLR agonists as immunomodulators for treating chronic hepatitis B: an overview","volume":"22","author":"Kayesh","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nrm1644","article-title":"MicroRNA biogenesis: coordinated cropping and dicing","volume":"6","author":"Kim","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e1640","DOI":"10.1002\/wrna.1640","article-title":"Artificial miRNAs as therapeutic tools: challenges and opportunities","volume":"12","author":"Kotowska-Zimmer","year":"2021","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1021\/acsnano.8b01516","article-title":"On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA","volume":"12","author":"Kulkarni","year":"2018","journal-title":"ACS Nano"},{"key":"B71","doi-asserted-by":"publisher","first-page":"21733","DOI":"10.1039\/c9nr09347h","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1097\/hep.0000000000000428","article-title":"Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation","volume":"78","author":"Kum","year":"2023","journal-title":"Hepatology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.coviro.2021.10.002","article-title":"Immunotherapy and therapeutic vaccines for chronic HBV infection","volume":"51","author":"Lang-Meli","year":"2021","journal-title":"Curr. Opin. Virology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"14029","DOI":"10.1039\/d1ra00878a","article-title":"Evaluation of DNA segments in 2\u2032-modified RNA sequences in designing efficient splice switching antisense oligonucleotides","volume":"11","author":"Le","year":"2021","journal-title":"RSC Adv."},{"key":"B75","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s11938-019-00236-3","article-title":"Updates on chronic HBV: current challenges and future goals","volume":"17","author":"Lee","year":"2019","journal-title":"Curr. Treat. Options Gastroenterology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature01957","article-title":"The nuclear RNase III Drosha initiates microRNA processing","volume":"425","author":"Lee","year":"2003","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1053\/j.gastro.2023.02.014","article-title":"Bepirovirsen\u2014A new therapy for chronic hepatitis B infection","volume":"165","author":"Lens","year":"2023","journal-title":"Gastroenterology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrd4359","article-title":"Therapeutic targeting of microRNAs: current status and future challenges","volume":"13","author":"Li","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1097\/cm9.0000000000003178","article-title":"Current trends and advances in antiviral therapy for chronic hepatitis B","volume":"137","author":"Li","year":"","journal-title":"Chin. Med. J."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e31924","DOI":"10.1016\/j.heliyon.2024.e31924","article-title":"Analysis of the pharmacokinetics and efficacy of RBD1016 - a GalNAc-siRNA targeting Hepatitis B Virus X gene using semi-mechanistic PK\/PD model","volume":"10","author":"Li","year":"","journal-title":"Heliyon"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-Dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.ymthe.2020.10.010","article-title":"DUX4 transcript knockdown with antisense 2\u2032-O-Methoxyethyl gapmers for the treatment of facioscapulohumeral muscular dystrophy","volume":"29","author":"Lim","year":"2021","journal-title":"Mol. Ther."},{"key":"B83","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(22)00537-2","article-title":"Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection","volume-title":"Annual meeting of the european association for the study of the liver (EASL) 2022","author":"Lim","year":""},{"key":"B84","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/s0168-8278(22)00537-2","article-title":"Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection","volume":"77","author":"Lim","year":"","journal-title":"J. Hepatology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","article-title":"The scientific basis of combination therapy for chronic hepatitis B functional cure","volume":"20","author":"Lim","year":"2023","journal-title":"Nat. Rev. Gastroenterology and Hepatology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.3390\/cells11172654","article-title":"Small nucleolar RNAs and their comprehensive biological functions in hepatocellular carcinoma","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"B87","article-title":"Pharmacokinetics, safety, and tolerability of the siRNA TQA3038 in healthy chinese volunteers","volume-title":"Annual meeting of the American association for the study of liver diseases (AASLD) 2024","author":"Liu","year":"2024"},{"key":"B88","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/biom15030376","article-title":"The progress and evolving trends in nucleic-acid-based therapies","volume":"15","author":"Liu","year":"2025","journal-title":"Biomolecules"},{"key":"B89","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.cld.2021.07.001","article-title":"Novel therapies that May cure chronic hepatitis B virus","volume":"25","author":"Loglio","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2165\/11318190-000000000-00000","article-title":"RNA interference technologies and therapeutics","volume":"23","author":"L\u00f3pez-Fraga","year":"2009","journal-title":"BioDrugs"},{"key":"B91","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jhep.2015.10.023","article-title":"Mopping up miRNA: an integrated HBV transcript disrupts liver homeostasis by sequestering miR-122","volume":"64","author":"Luna","year":"2016","journal-title":"J. Hepatology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.omtn.2017.04.007","article-title":"Sustained inhibition of HBV replication in vivo after systemic injection of AAVs encoding artificial antiviral primary MicroRNAs","volume":"7","author":"Maepa","year":"2017","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B93","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/14728222.2021.1915990","article-title":"Hepatitis B virus: promising drug targets and therapeutic implications","volume":"25","author":"Maepa","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.3390\/molecules25112692","article-title":"Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy","volume":"25","author":"Mainini","year":"2020","journal-title":"Molecules"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.3390\/microorganisms11112731","article-title":"The connection between MiR-122 and lymphocytes in patients receiving treatment for chronic hepatitis B virus infection","volume":"11","author":"Manea","year":"2023","journal-title":"Microorganisms"},{"key":"B96","doi-asserted-by":"publisher","first-page":"105366","DOI":"10.1016\/j.antiviral.2022.105366","article-title":"Long-term and efficient inhibition of hepatitis B virus replication by AAV8-delivered artificial microRNAs","volume":"204","author":"Mao","year":"2022","journal-title":"Antivir. Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2217\/fmb.13.87","article-title":"Recent advances in developing nucleic acid-based HBV therapy","volume":"8","author":"Marimani","year":"2013","journal-title":"Future Microbiol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1089\/nat.2023.0014","article-title":"New oligonucleotide 2\u2032-O-Alkyl N3\u2032\u2192P5\u2032 (Thio)-Phosphoramidates as potent antisense agents: physicochemical properties and biological activity","volume":"33","author":"Mart\u00ednez-Montero","year":"2023","journal-title":"Nucleic Acid. Ther."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e1627","DOI":"10.1002\/wrna.1627","article-title":"microRNA strand selection: unwinding the rules","volume":"12","author":"Medley","year":"2021","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"B100","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1016\/j.apsb.2024.05.008","article-title":"Current status and trends in small nucleic acid drug development: leading the future","volume":"14","author":"Miao","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"B101","doi-asserted-by":"publisher","first-page":"61S","DOI":"10.1002\/hep.1840070711","article-title":"Structure and expression of the hepatitis B virus genome","volume":"7","author":"Michel","year":"1987","journal-title":"Hepatology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"},{"key":"B103","doi-asserted-by":"publisher","first-page":"236","DOI":"10.5582\/ddt.2016.01061","article-title":"Smart polymeric nanocarriers for small nucleic acid delivery","volume":"10","author":"Miyata","year":"2016","journal-title":"Drug Discov. and Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3390\/v14040657","article-title":"HBsAg loss as a treatment endpoint for chronic HBV infection: HBV cure","volume":"14","author":"Moini","year":"2022","journal-title":"Viruses"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"B106","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s12951-024-03004-3","article-title":"Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates","volume":"22","author":"Nguyen","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cbpa.2019.02.009","article-title":"Recent advances in the development of HBV capsid assembly modulators","volume":"50","author":"Nijampatnam","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21505594.2022.2093444","article-title":"Novel therapeutic strategies for chronic hepatitis B","volume":"13","author":"Phillips","year":"2022","journal-title":"Virulence"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/cbdv.201100081","article-title":"An overview of sugar\u2010modified oligonucleotides for antisense therapeutics","volume":"8","author":"Prakash","year":"2011","journal-title":"Chem. and Biodivers."},{"key":"B111","doi-asserted-by":"publisher","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennaryN-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"177083","DOI":"10.1016\/j.ejphar.2024.177083","article-title":"RNAi in psoriasis: a melodic exploration of miRNA, shRNA, and amiRNA with a spotlight on siRNA","volume":"985","author":"Purewal","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e70010","DOI":"10.1002\/jex2.70010","article-title":"5-Fluorouracil treatment represses pseudouridine-containing miRNA export into extracellular vesicles","volume":"3","author":"Qu","year":"2024","journal-title":"J. Extracell. Biol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1111\/bph.15972","article-title":"Small interfering RNA: discovery, pharmacology and clinical development\u2014An introductory review","volume":"180","author":"Ranasinghe","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cell.2005.10.020","article-title":"Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation","volume":"123","author":"Rand","year":"2005","journal-title":"Cell"},{"key":"B116","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4103\/0973-029X.140762","article-title":"MicroRNAs - Biology and clinical applications","volume":"18","author":"Ranganathan","year":"2014","journal-title":"J. Oral Maxillofac. Pathol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1021\/acs.accounts.9b00101","article-title":"Theranostic nanoparticles for RNA-based cancer treatment","volume":"52","author":"Revia","year":"2019","journal-title":"Accounts Chem. Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"101128","DOI":"10.1016\/j.jhepr.2024.101128","article-title":"HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx","volume":"6","author":"Ringelhan","year":"2024","journal-title":"JHEP Rep."},{"key":"B119","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B120","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1136\/gutjnl-2023-331396","article-title":"TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism","volume":"73","author":"Roca Suarez","year":"2024","journal-title":"Gut"},{"key":"B121","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/17460441.2024.2440095","article-title":"Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges","volume":"20","author":"Ruchi","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"key":"B122","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B123","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","article-title":"Lipid nanoparticles for nucleic acid delivery: current perspectives","author":"Samaridou","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B124","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1093\/nar\/gkac539","article-title":"From bench to bedside: improving the clinical safety of GalNAc\u2013siRNA conjugates using seed-pairing destabilization","volume":"50","author":"Schlegel","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"B125","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1021\/acs.bioconjchem.3c00393","article-title":"Diligent design enables Antibody-ASO conjugates with optimal pharmacokinetic properties","volume":"34","author":"Sela","year":"2023","journal-title":"Bioconjugate Chem."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/nar\/gkaa031","article-title":"Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides","volume":"48","author":"Seth","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B127","doi-asserted-by":"publisher","first-page":"S1152","DOI":"10.1016\/s0168-8278(23)03287-7","article-title":"Safety and antiviral activity of RBD1016, a RNAi therapeutic, in Chinese subjects with chronic hepatitis B virus (HBV) infection","volume":"78","author":"Seto","year":"2023","journal-title":"J. Hepatology"},{"key":"B128","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3390\/ijms25031469","article-title":"Trials and tribulations of MicroRNA therapeutics","volume":"25","author":"Seyhan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B130","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","article-title":"Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index","volume":"37","author":"Shen","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4254\/wjh.v7.i3.498","article-title":"MiR-122 in hepatitis B virus and hepatitis C virus dual infection","volume":"7","author":"Song","year":"2015","journal-title":"World J. Hepatol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/13543784.2017.1333105","article-title":"New antivirals for the treatment of chronic hepatitis B","volume":"26","author":"Soriano","year":"2017","journal-title":"Expert Opin. Investigational Drugs"},{"key":"B133","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid. Ther."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1758-907X-3-1","article-title":"Inhibition of microRNA function by antimiR oligonucleotides","volume":"3","author":"Stenvang","year":"2012","journal-title":"Silence"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/nar\/gky059","article-title":"Editorial: nucleic acids research and nucleic acid therapeutics","volume":"46","author":"Stoddard","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B136","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41392-024-02035-4","article-title":"Nucleic acid drugs: recent progress and future perspectives","volume":"9","author":"Sun","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"B137","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1126\/science.282.5388.430","article-title":"RNAi in C. elegans: soaking in the genome sequence","volume":"282","author":"Tabara","year":"1998","journal-title":"Science"},{"key":"B138","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/nat.2022.0054","article-title":"Drug metabolism and pharmacokinetics of antisense oligonucleotide therapeutics: typical profiles, evaluation approaches, and points to consider compared with small molecule drugs","volume":"33","author":"Takakusa","year":"2023","journal-title":"Nucleic Acid. Ther."},{"key":"B139","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2017.05.025","article-title":"microRNA inhibitors: natural and artificial sequestration of microRNA","volume":"407","author":"Tang","year":"2017","journal-title":"Cancer Lett."},{"key":"B140","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/cm9.0000000000001994","article-title":"Advances in new antivirals for chronic hepatitis B","volume":"135","author":"Tang","year":"2022","journal-title":"Chin. Med. J."},{"key":"B141","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2174\/1566523214666141224095610","article-title":"miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir","volume":"15","author":"Thakral","year":"2015","journal-title":"Curr. Gene Ther."},{"key":"B142","doi-asserted-by":"publisher","first-page":"105864","DOI":"10.1016\/j.phrs.2021.105864","article-title":"GalNAc-siRNA conjugates: prospective tools on the frontier of anti-viral therapeutics","volume":"173","author":"Thangamani","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1021\/acsinfecdis.8b00191","article-title":"ARB-1740, a RNA interference therapeutic for chronic hepatitis B infection","volume":"5","author":"Thi","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"B144","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1021\/acsinfecdis.4c00514","article-title":"Control of hepatitis B virus with imdusiran, a small interfering RNA therapeutic","volume":"10","author":"Thi","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"B145","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/emmm.200900023","article-title":"RNAi\u2010based therapeutics\u2013current status, challenges and prospects","volume":"1","author":"Tiemann","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"B146","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","article-title":"Overview of hepatitis B viral replication and genetic variability","volume":"64","author":"Tong","year":"2016","journal-title":"J. Hepatology"},{"key":"B147","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41598-017-00387-2","article-title":"Natural killer cell activation contributes to hepatitis B viral control in a mouse model","volume":"7","author":"Tong","year":"2017","journal-title":"Sci. Rep."},{"key":"B148","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/pharmaceutics13030428","article-title":"Delivery systems for nucleic acids and proteins: barriers, cell capture pathways and nanocarriers","volume":"13","author":"Torres-Vanegas","year":"2021","journal-title":"Pharmaceutics"},{"key":"B149","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/s0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Tr\u00e9po","year":"2014","journal-title":"Lancet"},{"key":"B150","doi-asserted-by":"publisher","first-page":"104925","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antivir. Res."},{"key":"B151","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/v9040075","article-title":"HBV DNA integration: molecular mechanisms and clinical implications","volume":"9","author":"Tu","year":"2017","journal-title":"Viruses"},{"key":"B152","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"B153","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.3390\/v14092052","article-title":"Oligonucleotide-based therapies for chronic HBV infection: a primer on biochemistry, mechanisms and antiviral effects","volume":"14","author":"Vaillant","year":"2022","journal-title":"Viruses"},{"key":"B154","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/j.jhep.2022.09.002","article-title":"Bepirovirsen\/GSK3389404: antisense or TLR9 agonists?","volume":"78","author":"Vaillant","year":"2023","journal-title":"J. Hepatology"},{"key":"B155","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/cbic.201402551","article-title":"Base modification strategies to modulate immune stimulation by an siRNA","volume":"16","author":"Valenzuela","year":"2014","journal-title":"ChemBioChem"},{"key":"B156","doi-asserted-by":"publisher","first-page":"851","DOI":"10.15252\/emmm.201100899","article-title":"Development of microRNA therapeutics is coming of age","volume":"6","author":"van Rooij","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"B157","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1021\/cb200070k","article-title":"Phenylpyrrolocytosine as an unobtrusive base modification for monitoring activity and cellular trafficking of siRNA","volume":"6","author":"Wahba","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.canlet.2018.07.019","article-title":"Dysregulation of miRNA in chronic hepatitis B is associated with hepatocellular carcinoma risk after nucleos(t)ide analogue treatment","volume":"434","author":"Wakasugi","year":"2018","journal-title":"Cancer Lett."},{"key":"B159","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(24)00610-X","article-title":"A phase 1, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of AHB-137 in Chinese healthy volunteers and subjects with chronic hepatitis B","volume-title":"The european association for the study of the liver (EASL) 2024","author":"Wang","year":"2024"},{"key":"B160","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.biopha.2018.01.097","article-title":"miR-146 promotes HBV replication and expression by targeting ZEB2","volume":"99","author":"Wang","year":"2018","journal-title":"Biomed. and Pharmacother."},{"key":"B161","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.bbrc.2017.03.171","article-title":"miR-101 suppresses HBV replication and expression by targeting FOXO1 in hepatoma carcinoma cell lines","volume":"487","author":"Wang","year":"2017","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B162","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/bjc.2016.239","article-title":"Impact of non-neoplastic vs intratumoural hepatitis B viral DNA and replication on hepatocellular carcinoma recurrence","volume":"115","author":"Wang","year":"2016","journal-title":"Br. J. Cancer"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3390\/pathogens11101116","article-title":"Advances in immunotherapy for hepatitis B","volume":"11","author":"Wang","year":"2022","journal-title":"Pathogens"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3390\/v13081463","article-title":"Mechanism of hepatitis B virus cccDNA formation","volume":"13","author":"Wei","year":"2021","journal-title":"Viruses"},{"key":"B165","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/gm149","article-title":"Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection","volume":"2","author":"Weinberg","year":"2010","journal-title":"Genome Med."},{"key":"B166","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking Down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"B167","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrg3978","article-title":"Knocking down disease: a progress report on siRNA therapeutics","volume":"16","author":"Wittrup","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J. Hepatology"},{"key":"B169","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3390\/v13040581","article-title":"RNA interference therapy for chronic hepatitis B predicts the importance of addressing viral integration when developing novel cure strategies","volume":"13","author":"Wooddell","year":"2021","journal-title":"Viruses"},{"key":"B170","unstructured":"Global health sector strategy on viral hepatitis, 2016-2021\n          \n          \n          2016"},{"key":"B171","unstructured":"Global hepatitis report 2024: action for access in low- and middle-income countries\n          \n          \n          2024"},{"key":"B172","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12929-015-0199-y","article-title":"Natural history of chronic hepatitis B virus infection from infancy to adult life - the mechanism of inflammation triggering and long-term impacts","volume":"22","author":"Wu","year":"2015","journal-title":"J. Biomed. Sci."},{"key":"B173","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1038\/ncomms4459","article-title":"2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity","volume":"5","author":"Wu","year":"2014","journal-title":"Nat. Commun."},{"key":"B174","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1053\/j.gastro.2018.07.057","article-title":"Development of direct-acting antiviral and host-targeting agents for treatment of hepatitis B virus infection","volume":"156","author":"Xia","year":"2019","journal-title":"Gastroenterology"},{"key":"B175","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1021\/acsinfecdis.8b00337","article-title":"Treatment of chronic hepatitis B virus infection using small molecule modulators of nucleocapsid assembly: recent advances and perspectives","volume":"5","author":"Yang","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"B176","doi-asserted-by":"publisher","first-page":"115128","DOI":"10.1016\/j.ejmech.2023.115128","article-title":"Overview of the development of HBV small molecule inhibitors","volume":"249","author":"Yang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"B177","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/antiox13060678","article-title":"The coming age of antisense oligos for the treatment of hepatic Ischemia\/Reperfusion (IRI) and other liver disorders: role of oxidative stress and potential antioxidant effect","volume":"13","author":"Yao","year":"2024","journal-title":"Antioxidants (Basel)"},{"key":"B178","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.bcp.2008.11.005","article-title":"Cross-species comparison of in vivo PK\/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100","volume":"77","author":"Yu","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat. Med."},{"key":"B180","doi-asserted-by":"publisher","first-page":"S876","DOI":"10.1016\/s0168-8278(22)02045-1","article-title":"Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects","volume":"77","author":"Yuen","year":"","journal-title":"J. Hepatology"},{"key":"B181","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"","journal-title":"N. Engl. J. Med."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"","journal-title":"J. Hepatology"},{"key":"B183","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/s2468-1253(23)00148-6","article-title":"Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial","volume":"8","author":"Yuen","year":"","journal-title":"Lancet Gastroenterology and Hepatology"},{"key":"B184","article-title":"48 weeks of AB-729 + nucleos(t)ide analogue (NA) therapy results in profound, sustained HBsAg declines in both HBeAg+ and HBeAg- subjects which are maintained in HBeAg- subjects who have discontinued all therapy","volume-title":"Global hepatitis summit","author":"Yuen","year":""},{"key":"B185","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/s2468-1253(24)00237-1","article-title":"VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study","volume":"9","author":"Yuen","year":"2024","journal-title":"Lancet Gastroenterology and Hepatology"},{"key":"B186","doi-asserted-by":"publisher","first-page":"399","DOI":"10.14218\/JCTH.2021.00062","article-title":"HBV integration induces complex interactions between host and viral genomic functions at the insertion site","volume":"9","author":"Zhang","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s10565-021-09684-z","article-title":"Exosomes derived from hepatitis B virus-infected hepatocytes promote liver fibrosis via miR-222\/TFRC axis","volume":"39","author":"Zhang","year":"","journal-title":"Cell Biol. Toxicol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2022.08.014","article-title":"Nucleic acid-based therapy for brain cancer: challenges and strategies","volume":"350","author":"Zhang","year":"","journal-title":"J. Control. Release"},{"key":"B189","doi-asserted-by":"publisher","first-page":"105782","DOI":"10.1016\/j.antiviral.2023.105782","article-title":"Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy","volume":"221","author":"Zhao","year":"2024","journal-title":"Antivir. Res."},{"key":"B190","doi-asserted-by":"publisher","first-page":"1075916","DOI":"10.3389\/fimmu.2022.1075916","article-title":"Hepatitis B functional cure and immune response","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Immunol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1021\/jo8016742","article-title":"Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2\u2032,4\u2032-Carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties","volume":"74","author":"Zhou","year":"2008","journal-title":"J. Org. Chem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1633001\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T05:32:10Z","timestamp":1758864730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1633001\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":191,"alternative-id":["10.3389\/fphar.2025.1633001"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1633001","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"article-number":"1633001"}}